Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 21, 2025 07:00 ET | Source: Rapport Therapeutics, Inc.

Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual Meeting

Rapport will present two encore posters at the American Academy of Neurology Annual Mtg - data on RAP-219, which is in current Ph2a trial in focal epilepsy
March 11, 2025 07:00 ET | Source: Rapport Therapeutics, Inc.

Rapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Rapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
March 03, 2025 07:00 ET | Source: Rapport Therapeutics, Inc.

Rapport Therapeutics Announces Appointment of Dr. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine Development

Rapport appoints Dr. Jeffrey Sevigny as CMO, a physician-scientist with more than 15 years of translational and clinical drug development
February 24, 2025 07:00 ET | Source: Rapport Therapeutics, Inc.

Rapport Therapeutics to Participate in Upcoming Investor Conferences

Rapport Therapeutics will participate in fireside chats at the upcoming TD Cowen 45th Annual Health Care Conference and Stifel 2025 Virtual CNS Forum.
January 09, 2025 09:12 ET | Source: Rapport Therapeutics, Inc.

CORRECTION -- Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders

Rapport announced new data from its Phase 1 PET and MAD-2 trials for RAP-219 being studied as a novel precision medicine for patients with CNS disorders.
January 09, 2025 07:00 ET | Source: Rapport Therapeutics, Inc.

Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders

Rapport announced new data from its Phase 1 PET and MAD-2 trials for RAP-219 being studied as a novel precision medicine for patients with CNS disorders.
December 06, 2024 12:01 ET | Source: Rapport Therapeutics, Inc.

Rapport Therapeutics Presents Data Demonstrating Consistent Association Between Decreases in RNS Measured Long Episodes and Meaningful Reductions in Clinical Seizures

Rapport presents new data on the linear relationship between a seizure biomarker used in the company's RAP-219 POC trial and clinical seizures.
April 15, 2024 08:00 ET | Source: Neurona Therapeutics

Neurona Therapeutics Presents Positive Clinical Update from NRTX-1001 Cell Therapy Trial in Adults with Drug-resistant Focal Epilepsy at American Academy of Neurology (AAN) 2024 Annual Meeting

NRTX-1001 administration has been well-tolerated in all individuals treated to date 4 of 5 subjects treated with the lower dose of NRTX-1001 report >50% seizure reduction 3 of 5 subjects report...
June 29, 2022 16:05 ET | Source: ClearPoint Neuro, Inc.

ClearPoint Neuro Congratulates Neurona Therapeutics on Dosing of Initial Subject in First Clinical Trial of Regenerative Human Cell Therapy in Adults with Drug-Resistant Focal Epilepsy

SOLANA BEACH, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the...
November 08, 2021 16:05 ET | Source: ClearPoint Neuro, Inc.

ClearPoint Neuro Congratulates Neurona Therapeutics on IND Clearance for Neural Cell Therapy NRTX-1001 in Chronic Focal Epilepsy Patients

SOLANA BEACH, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the...